Literature DB >> 9682396

Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine.

T E Greenway1, J H Eldridge, G Ludwig, J K Staas, J F Smith, R M Gilley, S M Michalek.   

Abstract

Venezuelan equine encephalomyelitis (VEE) virus, a member of the family Togaviridae, genus Alphavirus, causes disease in humans and equids. The virus is normally transmitted by the bite of an infected mosquito however, it can also be highly infectious by aerosol. The purpose of the present study was to determine the effectiveness of formalin-fixed, 60Co-irradiated VEE virus microencapsulated in poly DL-lactide-co-glycolide in inducing immune responses protective against aerosol challenge with virulent VEE virus. Balb/c mice were primed by subcutaneous injection of microencapsulated VEE virus vaccine, followed 30 days later by a single immunization with the same vaccine given via the oral, intratracheal (i.t.) or subcutaneous (s.c.) route. Mice boosted by the i.t. or s.c. route had higher plasma IgG anti-VEE virus levels than orally immunized animals. The responses in the former groups were similar in magnitude to those seen in mice primed and boosted by the i.t. route. Antibody activity was detected in bronchial-alveolar and intestinal washes, fecal extracts and saliva from immunized animals. The levels of IgG and IgA antibody activity in bronchial-alveolar wash fluids from mice boosted by the i.t. route were higher than those seen in animals immunized by the oral or s.c. route with the microsphere vaccine. Mice immunized with the microencapsulated VEE virus vaccine were protected from lethal VEE virus infection following aerosol challenge at approximately three months after the initial immunization. Mucosal immunization via the i.t. route appeared to be the most effective regimen, since 100% of the mice resisted aerosol challenge.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9682396     DOI: 10.1016/s0264-410x(98)00008-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  Veterinary vaccine nanotechnology: pulmonary and nasal delivery in livestock animals.

Authors:  Daniella Calderon-Nieva; Kalhari Bandara Goonewardene; Susantha Gomis; Marianna Foldvari
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

2.  Pegylated alpha interferon is an effective treatment for virulent venezuelan equine encephalitis virus and has profound effects on the host immune response to infection.

Authors:  R A Lukaszewski; T J Brooks
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.

Authors:  Shannon S Martin; Russell R Bakken; Cathleen M Lind; Patricia Garcia; Erin Jenkins; Pamela J Glass; Michael D Parker; Mary Kate Hart; Donald L Fine
Journal:  Vaccine       Date:  2010-03-01       Impact factor: 3.641

Review 4.  Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.

Authors:  Yuchen Fan; James J Moon
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-04-01

5.  Acute infection with venezuelan equine encephalitis virus replicon particles catalyzes a systemic antiviral state and protects from lethal virus challenge.

Authors:  Jennifer L Konopka; Joseph M Thompson; Alan C Whitmore; Drue L Webb; Robert E Johnston
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

6.  Inhibition of multiple strains of Venezuelan equine encephalitis virus by a pool of four short interfering RNAs.

Authors:  Lyn O'Brien
Journal:  Antiviral Res       Date:  2006-12-04       Impact factor: 5.970

7.  Biodegradable nanoparticle-entrapped vaccine induces cross-protective immune response against a virulent heterologous respiratory viral infection in pigs.

Authors:  Varun Dwivedi; Cordelia Manickam; Basavaraj Binjawadagi; Dechamma Joyappa; Gourapura J Renukaradhya
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

Review 8.  Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases.

Authors:  Malgorzata Smola; Thierry Vandamme; Adam Sokolowski
Journal:  Int J Nanomedicine       Date:  2008
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.